Skip to content
Search

Latest Stories

AstraZeneca to make billion virus vaccine doses if tests succeed

AstraZeneca expects to be able to deliver a billion doses of a possible Covid-19 vaccine this year and next if tests are successful, adding on Thursday it should shortly get results of an early stage clinical trial.

The British drugmaker said it had signed the first agreements to supply at least 400 million doses of the vaccine, which it is developing with Oxford University.


It said it recognised the vaccine might not work but if results from the early stage tests were positive, they would lead to late stage trials in several countries.

Only a handful of the vaccines in development have advanced to human trials, an indicator of safety and efficacy, and the stage at which most fail.

There are currently no approved treatments or vaccines for Covid-19 being tested by pharmaceutical giants across the world, with governments, drugmakers and researchers working on around 100 programmes and experts predicting a safe and effective means of preventing the disease could take 12 to 18 months to develop.

AstraZeneca also said in a statement that it had received more than $1 billion from the US Biomedical Advanced Research and Development Authority for development, production and delivery of the potential vaccine.

It said the Covid-19 vaccine it was testing would include a planned late-stage clinical trial with 30,000 participants and a paediatric trial, adding that it planned to start supplying the vaccine in Britain in September.

Other drugmakers including Pfizer Inc , Johnson & Johnson and Sanofi are also in various stages of vaccine development.

US based Inovio Pharmaceuticals said on Wednesday (20) its experimental vaccine produced protective antibodies and immune system responses in mice and guinea pigs.

And Moderna this week released positive data for its potential vaccine, which it said produced protective antibodies in a small group of healthy volunteers.

AstraZeneca said it was engaging with international bodies, including the World Health Organization, for the fair allocation and distribution of the potential vaccine around the world.

(Reuters)

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less